Editor's Note

With this issue, the journal *HeartDrug* will be incorporated within *Cardiology*. This development is a step toward achieving the goals for additional emphases in *Cardiology* that I delineated in my editorial of August 5, 2005. These goals included an increased exposure of issues relating to cardiovascular clinical pharmacology. The opportunity to incorporate *HeartDrug*, an excellent periodical devoted specifically to this area and affiliated with the European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology and Drug Therapy (WG-3), will enable the incorporation of leading edge research and reviews concerning the evidentiary basis for drug therapy, including an emphasis on trial science. The rapidly growing armamentarium of drugs (and devices) that relieve debility *and* prolong life presents cardiologists and patients with increasingly complex choices and management issues. Resolution of these issues requires scientifically valid data that must be communicated effectively to the medical community. With the incorporation of *HeartDrug*, *Cardiology* now is better positioned than ever before to provide this important service. It is our great good fortune that the Editor of *HeartDrug*, Dr. Dan Atar, has agreed to become an Associate Editor of *Cardiology* to lead this new effort. We hope the readership of *Cardiology* will benefit from this initiative and that investigators in cardiovascular clinical pharmacology will find *Cardiology* an appropriate venue in which to report their research.

Jeffrey S. Borer